# Understanding Neurotransmitter Systems in Alzheimer’s Disease > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/neurotransmitter-systems-alzheimers-disease-overview/ > **Published:** 2026-03-28T08:17:38-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:36:18-04:00 > **Clinical Summary:** Explore neurotransmitter systems Alzheimer's disease dysfunction and their role in cognitive decline and treatment challenges. --- CED Clinical Relevance  #50Monitored Relevance  Early-stage or contextual signal requiring further evidence before action. 🔬 Evidence Watch  |  CED Clinic Alzheimer’SNeurotransmittersDementiaCognitive-DeclineReview Journal Current issues in molecular biology Study Type Clinical Study Population Human participants Why This Matters This comprehensive review maps how multiple neurotransmitter systems deteriorate in Alzheimer’s disease, providing clinicians with a mechanistic framework for understanding why current single-target therapies have limited efficacy. Understanding these interconnected pathways helps explain the complex symptom profile patients experience and may inform more effective treatment approaches. Clinical Summary This review synthesizes current understanding of neurotransmitter system dysfunction in Alzheimer’s disease beyond the traditional amyloid-tau framework. The authors detail how cholinergic degeneration correlates with [cognitive decline](https://cedclinic.com/cannabis-cognitive-safety-in-older-adults/), glutamatergic excitotoxicity accelerates neuronal damage through NMDA/AMPA receptor alterations, and GABAergic system disruption creates pathological hyperexcitability. The review emphasizes that AD involves simultaneous dysfunction across multiple neurotransmitter networks, not sequential failure of individual systems. While comprehensive, this is a narrative review rather than original research, limiting direct clinical applications. Dr. Caplan’s Take “This reinforces what I see clinically – AD patients don’t fit into neat pharmacological boxes because multiple brain systems fail simultaneously. The multi-target dysfunction described here explains why single-mechanism drugs consistently disappoint in AD trials.” Clinical Perspective 🧠 Clinicians should recognize that AD symptoms reflect complex neurotransmitter network failure rather than isolated deficits. This understanding supports combination therapeutic approaches and helps explain why patients may respond differently to standard treatments. The framework also provides rationale for addressing multiple symptom domains simultaneously rather than treating cognitive and behavioral symptoms as separate entities. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Neurotransmitter%20Systems%20in%20Alzheimer%27s%20Disease.%20%40drcaplan&url=https%3A//pubmed.ncbi.nlm.nih.gov/41899485/)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//pubmed.ncbi.nlm.nih.gov/41899485/)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Neurotransmitter%20Systems%20in%20Alzheimer%27s%20Disease.%20--%20via%20%40drcaplan.bsky.social%20https%3A//pubmed.ncbi.nlm.nih.gov/41899485/)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://pubmed.ncbi.nlm.nih.gov/41899485/](https://pubmed.ncbi.nlm.nih.gov/41899485/) Table of Contents - [FAQ](#FAQ)[How do neurotransmitter changes in Alzheimer’s disease affect cognitive symptoms?](#How_do_neurotransmitter_changes_in_Alzheimer8217s_disease_affect_cognitive_symptoms) - [Why is the cholinergic system particularly important in Alzheimer’s disease treatment?](#Why_is_the_cholinergic_system_particularly_important_in_Alzheimer8217s_disease_treatment) - [What role does glutamate excitotoxicity play in Alzheimer’s disease progression?](#What_role_does_glutamate_excitotoxicity_play_in_Alzheimer8217s_disease_progression) - [How do GABA system changes contribute to Alzheimer’s symptoms?](#How_do_GABA_system_changes_contribute_to_Alzheimer8217s_symptoms) - [Does this research suggest new therapeutic approaches beyond current Alzheimer’s medications?](#Does_this_research_suggest_new_therapeutic_approaches_beyond_current_Alzheimer8217s_medications) - [Related](#Related) ## FAQ #### How do neurotransmitter changes in Alzheimer’s disease affect cognitive symptoms? Multiple neurotransmitter systems are disrupted in Alzheimer’s disease, with the cholinergic system showing early degeneration that directly correlates with [cognitive impairment](https://cedclinic.com/acute-effects-partial-cb1-receptor-agonists-cognition/). The glutamatergic system exhibits excitotoxicity from excess extracellular glutamate, while GABAergic alterations in parvalbumin-positive interneurons lead to hyperexcitability, all contributing to progressive [cognitive decline](https://cedclinic.com/cannabis-cognitive-safety-in-older-adults/). #### Why is the cholinergic system particularly important in Alzheimer’s disease treatment? The cholinergic system was historically the first neurotransmitter system associated with Alzheimer’s disease and suffers early degeneration of neurons and receptors. This early involvement and its direct correlation with [cognitive impairment](https://cedclinic.com/acute-effects-partial-cb1-receptor-agonists-cognition/) makes it a primary target for current FDA-approved treatments like cholinesterase inhibitors. #### What role does glutamate excitotoxicity play in Alzheimer’s disease progression? In Alzheimer’s disease, the glutamatergic system experiences increased extracellular glutamate levels and altered NMDA/AMPA receptor distribution, leading to excitotoxicity. This excessive stimulation exacerbates neuronal damage and contributes to the progressive brain degeneration characteristic of the disease. #### How do GABA system changes contribute to Alzheimer’s symptoms? The GABAergic system, which normally provides inhibitory balance in the brain, shows alterations in parvalbumin-positive interneurons in Alzheimer’s disease. These changes lead to neuronal hyperexcitability, disrupting the normal excitatory-inhibitory balance and potentially contributing to both cognitive and behavioral symptoms. #### Does this research suggest new therapeutic approaches beyond current Alzheimer’s medications? This comprehensive understanding of multiple neurotransmitter system dysfunction suggests that multi-target therapeutic approaches may be more effective than single-system interventions. Current treatments primarily target cholinergic and glutamatergic systems, but addressing GABAergic dysfunction and the complex interplay between systems could offer new therapeutic opportunities. {“@context”: “https://schema.org”, “@type”: “ScholarlyArticle”, “headline”: “Neurotransmitter Systems in Alzheimer’s Disease.”, “url”: “https://pubmed.ncbi.nlm.nih.gov/41899485/”, “about”: “current issues molecular biology clinical study”, “isPartOf”: “Current issues in molecular biology”} [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Gut cells prime T-cells to trigger brain inflammation in MS: Study](https://cedclinic.com/gut-brain-immune-axis-connection-ms-inflammation/) Explore how [immune system](https://cedclinic.com/fungal-contamination-cannabis-risks-arizona-preroll-recall/) interactions contribute to [brain inflammation](https://cedclinic.com/unknown-cannabinoid-receptor-brain-damage-relief/), relevant to neurodegenerative diseases like Alzheimer's. [Read More](https://cedclinic.com/gut-brain-immune-axis-connection-ms-inflammation/) [Fecal transplants ease motor symptoms in early Parkinson's: Study](https://cedclinic.com/gut-microbiome-parkinsons-disease-fecal-transplants-study/) Learn about novel therapeutic approaches targeting neurological symptoms, offering insights into neurodegenerative disease management. [Discover Insights](https://cedclinic.com/gut-microbiome-parkinsons-disease-fecal-transplants-study/) [Cannabis Use Disorder Treatment Europe Review](https://cedclinic.com/cannabis-use-disorder-treatment-europe-evidence-watch/) Review current evidence on [cannabis use disorder](https://cedclinic.com/sex-differences-cannabis-stress-reactivity-oxytocin/) treatments, highlighting advances in neurological and psychiatric care. [Explore Review](https://cedclinic.com/cannabis-use-disorder-treatment-europe-evidence-watch/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).